ANIP - ANIファ―マシュ―ティカルズ (ANI Pharmaceuticals Inc.) ANIファ―マシュ―ティカルズ

 ANIPのチャート


 ANIPの企業情報

symbol ANIP
会社名 ANI Pharmaceuticals Inc (ANIファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ANIファーマシューティカル(ANI Pharmaceuticals Inc.)は統合・専門的製薬会社である。同社はブランド医薬品とジェネリック医薬品の開発、製造、マーケティングに従事する。同社は抗癌剤(抗腫瘍剤)、ホルモンおよびステロイド、複合的製剤を提供する。同社はまた、他の製薬会社の請負製造を行う。製品には、ブランド医薬品とジェネリック医薬品を含む。ジェネリック医薬品はエリスロマイシンエチルコハク酸塩、メチルテストステロン(EEMT)を有するエステル化エストロゲン、エトドラクフェノフィブレート、フレカイニド、フルボキサミン、メタゾラミド、メトクロプラミドシロップニルタミド、ニモジピン、アヘンチンキ、オキシコドンカプセル、オキシコドン経口溶液、プロパフェノンおよびバンコマイシンなどを含む。ブランド製品にはコルテネーマ、インデラルLA、リトビッド、レグランおよびバンコシンが含まれる。同社の医薬品製造施設はミネソタ州ボーデットに位置する。   ANIファ―マシュ―ティカルズは米国の製薬会社。ブランドとジェネリックの医療用医薬品の開発、製造、販売に従事する。女性の性的健康、更年期障害、避妊と男性性腺機能低下症の治療用医薬品開発のほか、開発製品の対象は麻酔薬、抗がん薬、ホルモン・ステロイドおよび製剤を含む。本社はミネソタ州。   ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products.
本社所在地 210 Main Street West Baudette MN 56623 USA
代表者氏名 Robert E. Brown ロバートE.ブラウン
代表者役職名 Independent Chairman of the Board
電話番号 +1 218-634-3500
設立年月日 35278
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 173人
url www.anipharmaceuticals.com
nasdaq_url https://www.nasdaq.com/symbol/anip
adr_tso
EBITDA EBITDA(百万ドル) 62.04800
終値(lastsale) 54.83
時価総額(marketcap) 648570965.63
時価総額 時価総額(百万ドル) 656.49620
売上高 売上高(百万ドル) 189.20100
企業価値(EV) 企業価値(EV)(百万ドル) 806.10820
当期純利益 当期純利益(百万ドル) 13.49700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 ANI Pharmaceuticals Inc revenues increased 15% to $93.8M. Net income applicable to common stockholders increased 31% to $5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Stock-based Compensation in SGA decrease of 3% to $2.7M (expense).

 ANIPのテクニカル分析


 ANIPのニュース

   ANI Pharmaceuticals Says Its Supplemental NDA For Purified Cortrophin Gel Accepted  2021/08/31 11:40:13 Business Insider Markets
(RTTNews) - ANI Pharmaceuticals, Inc. (ANIP) on Tuesday said the FDA has accepted the company''s supplemental New Drug Application for Purified Cortrophin Gel for multiple indications including multiple sclerosis, rheumatoid arthritis, and nephrotic syndrome. A decision by the FDA on the application is expected on October 29, 2021.
   ANI Pharmaceuticals Announces FDA Acceptance of Purified Cortrophin® Gel Supplemental New Drug Application for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis, and Nephrotic Syndrome  2021/08/31 10:50:00 Business Wire
BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq:ANIP) today announced that the Companys supplemental New Drug Application (sNDA) for Purified Cortrophin® Gel (Cortrophin Gel) has been accepted by the U.S. Food and Drug Administration (FDA) for review. FDAs acceptance of our sNDA for Cortrophin Gel marks a significant milestone for ANI. With a PDUFA target action date of October 29, 2021, we are one step closer to bringing a much-needed produ
   ANI Pharmaceuticals, inc (ANIP) Q2 2021 Earnings Call Transcript  2021/08/06 18:31:15 The Motley Fool
ANIP earnings call for the period ending June 30, 2021.
   ANI Pharmaceuticals'' (ANIP) CEO Nikhil Lalwani on Q2 2021 Results - Earnings Call Transcript  2021/08/06 16:20:05 Seeking Alpha
   ANI Pharmaceuticals EPS beats by $0.07, beats on revenue  2021/08/06 11:38:30 Seeking Alpha
   ANI Pharmaceuticals Says Its Supplemental NDA For Purified Cortrophin Gel Accepted  2021/08/31 11:40:13 Business Insider Markets
(RTTNews) - ANI Pharmaceuticals, Inc. (ANIP) on Tuesday said the FDA has accepted the company''s supplemental New Drug Application for Purified Cortrophin Gel for multiple indications including multiple sclerosis, rheumatoid arthritis, and nephrotic syndrome. A decision by the FDA on the application is expected on October 29, 2021.
   ANI Pharmaceuticals Announces FDA Acceptance of Purified Cortrophin® Gel Supplemental New Drug Application for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis, and Nephrotic Syndrome  2021/08/31 10:50:00 Business Wire
BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq:ANIP) today announced that the Companys supplemental New Drug Application (sNDA) for Purified Cortrophin® Gel (Cortrophin Gel) has been accepted by the U.S. Food and Drug Administration (FDA) for review. FDAs acceptance of our sNDA for Cortrophin Gel marks a significant milestone for ANI. With a PDUFA target action date of October 29, 2021, we are one step closer to bringing a much-needed produ
   ANI Pharmaceuticals, inc (ANIP) Q2 2021 Earnings Call Transcript  2021/08/06 18:31:15 The Motley Fool
ANIP earnings call for the period ending June 30, 2021.
   ANI Pharmaceuticals'' (ANIP) CEO Nikhil Lalwani on Q2 2021 Results - Earnings Call Transcript  2021/08/06 16:20:05 Seeking Alpha
   ANI Pharmaceuticals EPS beats by $0.07, beats on revenue  2021/08/06 11:38:30 Seeking Alpha
   ANI Pharmaceuticals, inc (ANIP) Q2 2021 Earnings Call Transcript  2021/08/06 18:31:15 The Motley Fool
ANIP earnings call for the period ending June 30, 2021.
   ANI Pharmaceuticals'' (ANIP) CEO Nikhil Lalwani on Q2 2021 Results - Earnings Call Transcript  2021/08/06 16:20:05 Seeking Alpha
   ANI Pharmaceuticals EPS beats by $0.07, beats on revenue  2021/08/06 11:38:30 Seeking Alpha
   ANI Pharmaceuticals Reports Second Quarter 2021 Results  2021/08/06 11:24:00 Business Wire
BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ: ANIP) today announced business highlights and financial results for the three and six months ended June 30, 2021. Second Quarter and Recent Business Highlights: The Company refiled its supplemental new drug application (sNDA) for Cortrophin® Gel with the U.S. Food and Drug Administration (FDA or the Agency) on June 29, 2021; goal date is October 29, 2021; Acquisition of Novitium Pharma LLC (Novi
   ANI Pharmaceuticals Announces Refiling of Cortrophin sNDA with FDA Wire  2021/07/10 12:54:51 Business Wire
ANI Pharmaceuticals Announces Refiling of Cortrophin sNDA with FDA Business Wire

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ANIファ―マシュ―ティカルズ ANIP ANI Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)